Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Earnings Routine +

Canopy Growth Reports Fourth Quarter and Fiscal Year 2026 Financial Results; Delivers Q4 FY2026 Net Revenue Growth of 27% in Canada Medical and 68% in International Markets Cannabis

Balance sheet repair and MTL integration buy time, but margin compression and cash burn keep profitability distant.

By The Northwire Desk — AI Analysis Jun 15, 2026 · 07:00 WEED · 1.41 CANOPY GROWTH CORPORATION J
Executive Summary
  • Q4 FY2026 net revenue of $71.2M CAD (+10% YoY) and full-year FY2026 net revenue of $284.6M CAD (+6% YoY).
  • Canada medical cannabis delivered strong Q4 growth of 27% YoY; international markets surged 68% YoY in Q4 after resolving European supply chain constraints.
  • Completed the acquisition of MTL Cannabis, positioning the company as Canada’s leading medical cannabis provider by revenue.
  • Strategic recapitalization in January 2026 flipped the balance sheet from $172.6M net debt to $131.3M net cash.
  • Reported gross margin contracted to 12% in Q4 (vs 16% in Q4 FY2025) and 24% for FY2026 (vs 30% in FY2025). Adjusted gross margin improved to 27% in Q4 and 28% for FY2026.
  • $10.7M in inventory charges incurred in Q4, primarily from a post-MTL acquisition inventory review.
  • $67.1M in impairment and restructuring costs recorded in FY2026, mainly for goodwill/brand impairments and employee restructuring.
  • Net loss narrowed 21% YoY in Q4 and 49% YoY in FY2026.
  • Adjusted EBITDA loss narrowed 32% YoY in Q4 to $6.3M; full-year loss narrowed 14% to $20.2M.
  • Free cash flow outflow improved significantly to $69.1M from $176.6M in FY2025.
  • FY2027 Outlook targets net revenue growth, meaningful gross margin improvements, reduced operating expenses, and positive Adjusted EBITDA.
Material Impact
  • The news is Routine - Positive. The results reflect a continued "reset" narrative: revenue growth in core segments, balance sheet repair, and a clear path to positive Adj EBITDA in FY2027. However, the underlying fundamentals remain challenged: reported gross margins are compressed (12%), cash burn persists (FCF outflow $69.1M), and integration costs are still weighing on results. The stock's 6.6% decline into the print indicates the market had already priced in a soft quarter. There is no genuinely new, market-repricing catalyst here; it is a steady execution of the turnaround plan.
WEED · Price
Company Overview
  • Canopy Growth Corporation is a leading Canadian cannabis producer and a global medical cannabis player. The company operates across Canada (adult-use and medical), Europe, and Australia. Recent strategic moves include the acquisition of MTL Cannabis to strengthen its medical footprint and a strategic recapitalization to repair the balance sheet. The company is pivoting toward disciplined cost management, operational efficiency, and a path to sustainable profitability.
Read the original news release →

More from CANOPY GROWTH CORPORATION J

Jun 08, 2026 · 07:30

Product line extension and award recognition fail to offset structural margin pressures and market skepticism.

Other May 29, 2026 · 07:00

Accounting Restatement and Management Cease Trade Order Loom Over Germany Expansion

Regulatory May 15, 2026 · 17:00

Canopy Growth’s accounting stumble is a self-inflicted wound that muddies the recovery narrative just as operational momentum was building.

Other May 14, 2026 · 08:45

Canopy Growth’s latest product tweak gets swept into a wider European boom story, but the stock’s rebound remains more about survival than fireworks.

M&A / Property May 07, 2026 · 07:30

Canopy Growth Expands Medical Portfolio as Integration Risks Linger Despite Liquidity Boost

Production / Operations Apr 30, 2026 · 08:30

Canopy Growth Stabilizes Amidst Sector Edibles Momentum; MTL Integration Key to FY27 Profitability Path

Production / Operations